AFTPH

Across TCGA pan-cancer cohorts, AFTPH mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AFTPH data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AFTPH mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AFTPH expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where AFTPH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.537	0.267	<.001	71	view →
LSCC	DFS	Quartile	All	1.000	0.824	.004	21	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.514	.022	15	view →
LUAD	OS	Median	II,III,IV	1.000	0.807	.009	14	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
GBM	OS	Median	All	0.646	0.868	.019	4	view →
HNSC	DFS	Median	II,III,IV	0.755	0.567	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AFTPH–PDAC (DFS)

Open the PDAC breakdown →